Experts discuss how current coverage policies and prior authorization requirements affect continuous glucose monitoring (CGM) access and adoption rates, and how coverage barriers impact the ability to provide timely CGM access, particularly for patients who could benefit most.
Video content above is prompted by the following:
How do current coverage policies and prior authorization requirements affect CGM access and adoption rates?
How do coverage barriers impact your ability to provide timely CGM access, particularly for patients who could benefit most?
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More